Balyasny Asset Management
TPTX

Balyasny Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Balyasny Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-88,943
Closed -$6.69M – 3449
2022
Q2 		$6.69M Buy
+88,943
New +$3.95M 0.02% 817
2021
Q3 		– Sell
-43,550
Closed -$3.4M – 2595
2021
Q2 		$3.4M Buy
+43,550
New +$3.22M 0.02% 838
2020
Q4 		– Sell
-20,003
Closed -$1.75M – 1824
2020
Q3 		$1.75M Buy
+20,003
New +$1.39M 0.01% 873

Balyasny Asset Management's TPTX Position: Q3 2022 in Review

Balyasny Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 88,943 shares — an estimated $6.69M sold.

Balyasny Asset Management first reported a position in TPTX in Q3 2020 and held it in 3 quarters. The position peaked at $6.69M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Balyasny Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 88,943 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $6.69M.
  • Balyasny Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Balyasny Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $6.69M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.